COVIDome Explorer online portal launched to accelerate COVID-19 research on a global scale

NewsGuard 100/100 Score

To further accelerate COVID-19 research on a global scale, investigators from the University of Colorado Anschutz Medical Campus have created a multidimensional dataset, known as the COVIDome dataset, derived from hospitalized COVID-19 patients versus negative controls. The team has now launched a public online portal called the COVIDome Explorer to share that data in real time.

Today, a new paper published in the journal Cell Reports detailing how the datasets were generated while explaining how to use the COVIDome Explorer for rapid hypotheses testing, hypothesis generation and real-time discoveries by experts and non-experts.

"Our mission for the COVIDome Explorer is to enable the development of better prevention, diagnostic and therapeutic tools for the clinical management of COVID-19," said Joaquin Espinosa, PhD, professor at the University of Colorado School of Medicine and executive director at the Linda Crnic Institute for Down Syndrome on the CU Anschutz Medical Campus. "Although great progress has been made in all these areas, the speed of research for COVID-19 has been hampered by the lack of widely accessible, public datasets that can be analyzed and reanalyzed in real time by anyone."

He adds, "We expect that this online portal will rapidly accelerate COVID-19 data sharing, hypothesis testing and discoveries worldwide."

To create the COVIDome Explorer, experts in different areas of biomedical research across the CU Anschutz Medical Campus created multidimensional datasets in their labs. Those were collected and combined to be shared through the online portal. The datasets include demographics and clinical data, along with matched analysis of the whole blood transcriptome, analysis of the plasma and red blood cell metabolomes, deep immune phenotyping by mass cytometry and seroconversion assays.

The COVIDome datasets and corresponding Explorer were modeled after similar ongoing efforts in the Linda Crnic Institute for Down Syndrome, where members of the COVIDome team previously developed the Human Trisome Project and its TrisomExplorer data portal. Leveraging the leading-edge tools and technologies of the TrisomExplorer, the team was able to create the COVIDome Explorer in a matter of weeks and make it available to the public to help advance COVID-19 research.

The global health crisis imposed by the COVID-19 pandemic further emphasizes the need for rapid collaboration, open access to manuscripts under review and data sharing. Now more than ever, with the rise of the COVID-19 Delta variant and breakthrough infection rates rising, it's critical to have easy and timely access to COVID data to combat the pandemic and advance the best scientific data available."

Thomas Flaig, MD, Vice Chancellor of Research, CU Anschutz Medical Campus

The paper, which users are encouraged to read, details how to use the online dashboards and links to data files that guide users, such as catalogs of proteins, metabolites, cytokines and immune cells present in each dataset.

For example, to facilitate quick and broad access to the COVIDome dataset, each dataset (after data curation and quality control) is linked at the sample level with a unique identifier, enabling cross-referencing among platforms. Additionally, the COVIDome Explorer hosts six dashboards: Cohort, Transcriptome, Proteome, Cytokines, Metabolome, and Immune Maps. And each dashboard runs within its own isolated and protected environment.

The COVIDome Project is a partnership between the CU School of Medicine and the Office of the Vice Chancellor for Research, co-led by Joaquin Espinosa, PhD, and Thomas Flaig, MD. To learn more, visit https://medschool.cuanschutz.edu/covidome.

Source:
Journal reference:

Sullivan, K.D., et al. (2021) The COVIDome Explorer researcher portal. Cell Reports. doi.org/10.1016/j.celrep.2021.109527.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings